{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inhaled+budesonide+and+formoterol",
    "query": {
      "intervention": "Inhaled budesonide and formoterol"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 43,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inhaled+budesonide+and+formoterol&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T17:37:40.610Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03478696",
      "title": "A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "budesonide/formoterol",
          "type": "DRUG"
        },
        {
          "name": "albuterol/salbutamol",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match budesonide/formoterol",
          "type": "DRUG"
        },
        {
          "name": "tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "placebo to match tiotropium",
          "type": "DRUG"
        },
        {
          "name": "ELLIPTA",
          "type": "DEVICE"
        },
        {
          "name": "MDI",
          "type": "DEVICE"
        },
        {
          "name": "HandiHaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 732,
      "start_date": "2018-06-25",
      "completion_date": "2019-03-18",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-10-04T17:37:40.610Z",
      "location_count": 42,
      "location_summary": "Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03478696"
    },
    {
      "nct_id": "NCT02727660",
      "title": "A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disorder"
      ],
      "interventions": [
        {
          "name": "BFF MDI (PT009) 320/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BFF MDI (PT009) 160/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "FF MDI (PT005) 9.6 μg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 1876,
      "start_date": "2016-04-29",
      "completion_date": "2018-04-04",
      "has_results": true,
      "last_update_posted_date": "2019-09-26",
      "last_synced_at": "2026-10-04T17:37:40.610Z",
      "location_count": 121,
      "location_summary": "Dothan, Alabama • Huntsville, Alabama • Sheffield, Alabama + 107 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02727660"
    },
    {
      "nct_id": "NCT06075095",
      "title": "A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD (Chronic Obstructive Pulmonary Disease)"
      ],
      "interventions": [
        {
          "name": "BGF MDI HFO 320/14.4/9.6μg",
          "type": "DRUG"
        },
        {
          "name": "BGF MDI HFA 320/14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDI HFA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 297,
      "start_date": "2024-01-11",
      "completion_date": "2025-08-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-27",
      "last_synced_at": "2026-10-04T17:37:40.610Z",
      "location_count": 19,
      "location_summary": "Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06075095"
    },
    {
      "nct_id": "NCT05569421",
      "title": "A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Treatment A: BGF MDI HFO",
          "type": "DRUG"
        },
        {
          "name": "Treatment B: BGF MDI HFA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 108,
      "start_date": "2022-10-11",
      "completion_date": "2023-04-14",
      "has_results": true,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-10-04T17:37:40.610Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05569421"
    },
    {
      "nct_id": "NCT05689983",
      "title": "Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Asthma in Children",
        "Nonadherence, Medication"
      ],
      "interventions": [
        {
          "name": "Maintenance ICS and Symptom Driven SABA",
          "type": "DRUG"
        },
        {
          "name": "Symptom-driven budesonide/formoterol combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 55,
      "start_date": "2022-04-01",
      "completion_date": "2025-09-25",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-04T17:37:40.610Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05689983"
    },
    {
      "nct_id": "NCT05111262",
      "title": "Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Asthma",
        "Nonadherence, Medication"
      ],
      "interventions": [
        {
          "name": "Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-12-16",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-04T17:37:40.610Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05111262"
    },
    {
      "nct_id": "NCT02766608",
      "title": "Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disorder"
      ],
      "interventions": [
        {
          "name": "BFF MDI 320/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BFF MDI 160/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "FF MDI 9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BD MDI 320 μg",
          "type": "DRUG"
        },
        {
          "name": "Symbicort® TBH 400/12 μg BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 2389,
      "start_date": "2016-05-31",
      "completion_date": "2017-12-01",
      "has_results": true,
      "last_update_posted_date": "2019-09-24",
      "last_synced_at": "2026-10-04T17:37:40.610Z",
      "location_count": 83,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 70 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02766608"
    },
    {
      "nct_id": "NCT05322707",
      "title": "BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg",
          "type": "DRUG"
        },
        {
          "name": "Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cipla Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1485,
      "start_date": "2022-04-15",
      "completion_date": "2023-08-29",
      "has_results": false,
      "last_update_posted_date": "2023-08-30",
      "last_synced_at": "2026-10-04T17:37:40.610Z",
      "location_count": 1,
      "location_summary": "Medford, Oregon",
      "locations": [
        {
          "city": "Medford",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05322707"
    },
    {
      "nct_id": "NCT01136655",
      "title": "A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "80/2.25 μg Symbicort pMDI",
          "type": "DRUG"
        },
        {
          "name": "80/4.5 μg Symbicort pMDI",
          "type": "DRUG"
        },
        {
          "name": "Foradil Aerolizer 12 μg",
          "type": "DRUG"
        },
        {
          "name": "40 μg budesonide HFA pMDI",
          "type": "DRUG"
        },
        {
          "name": "placebo HFA pMDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 54,
      "start_date": "2010-09",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2013-10-31",
      "last_synced_at": "2026-10-04T17:37:40.610Z",
      "location_count": 20,
      "location_summary": "Huntington, California • Long Beach, California • Mission Viejo, California + 17 more",
      "locations": [
        {
          "city": "Huntington",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estate",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01136655"
    },
    {
      "nct_id": "NCT02157935",
      "title": "Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD Patients"
      ],
      "interventions": [
        {
          "name": "Symbicort",
          "type": "DRUG"
        },
        {
          "name": "Formoterol turbohaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Symbicort pMDI",
          "type": "OTHER"
        },
        {
          "name": "Placebo for Formoterol Turbohaler",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "40 Years to 95 Years"
      },
      "enrollment_count": 2026,
      "start_date": "2014-06-27",
      "completion_date": "2016-02-08",
      "has_results": true,
      "last_update_posted_date": "2017-11-07",
      "last_synced_at": "2026-10-04T17:37:40.610Z",
      "location_count": 224,
      "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 107 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02157935"
    }
  ]
}